This approval helps address an urgent unmet need, with about half of people living with early-stage NSCLC experiencing disease recurrence following surgery, despite adjuvant chemotherapy
Approximately half of all patients with metastatic breast cancer (mBC) express low levels of HER2
First and only AKT inhibitor approved in Japan for breast cancer patients with specific biomarker alterations
About 75% of all primary liver cancers in adults are HCC and up to 30% of HCC patients are eligible for embolisation
Furthering cell therapy ambition across oncology and autoimmune diseases
First-in-class AKT inhibitor has potential to reshape treatment for breast cancer patients
Approval based on results from TOPAZ-1 global Phase III trial and a Chinese patient
The agreement demonstrates a shared commitment to advance precision medicine and improve patient outcomes in the region
Approval based on DESTINY-Lung02 results where AstraZeneca and Daiichi Sankyo’s Enhertu demonstrated a confirmed objective response rate of 49% and median duration of response of 16.8 months in previously treated patients
Clinical data to date shows efti uniquely positioned to address entire NSCLC patient population through both chemo-free IO-IO and IO-IO-chemo triple combinations
Subscribe To Our Newsletter & Stay Updated
